Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


King Defense Against Generic ACE Inhibitors May Include Increased Spending

Executive Summary

King will consider increasing marketing spend behind Altace (ramipril) in the second half of the year to strengthen the drug's position against generics of other angiotension converting enzyme inhibitors, CEO Brian Markison said during an Aug. 9 earnings call

You may also be interested in...

Hypertension Rx Labels Should Include Product-Specific CV Data – Cmte.

Data on antihypertensives that have shown cardiovascular endpoint benefits in well-controlled trials should be included in labeling, FDA and the Cardiovascular & Renal Drugs Advisory Committee agreed at a June 15 meeting

Altace New Indications, Line Extensions Top King R&D Pipeline

New indications for the ACE inhibitor Altace top the list of pipeline projects being developed by King to fuel future growth, the company said during an investor presentation April 12

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts